IBEX Innovations: Transforming Osteoporosis Detection with HI NENC Support
A breakthrough in bone health detection is gaining momentum with IBEX Innovations, a UK-based company using advanced technology to assess bone density from standard X-ray images. With support from Health Innovation North East and North Cumbria (HI NENC), IBEX is bringing its solution to market, offering a new way to prevent osteoporosis and enable earlier intervention.
A smarter approach to bone health
Osteoporosis is a silent condition that weakens bones, making fractures more likely – particularly in women. Traditionally, risk is only assessed after a fracture has occurred, often requiring DEXA scans, which can be expensive and time-consuming.
IBEX has developed software that integrates with standard X-ray systems to assess bone density, meaning a simple wrist X-ray could help predict a patient’s risk of osteoporosis. This earlier detection could lead to timely lifestyle changes, medication and support, reducing fractures and easing pressure on hospitals.
IBEX is also embedding its technology into mammography equipment, allowing women to be screened opportunistically during routine breast screenings. This is particularly important for those at higher risk, such as women undergoing cancer treatment, where radiotherapy can weaken bones. By detecting osteoporosis earlier, this innovation could prevent fractures and improve long-term health outcomes.
How HI NENC has supported IBEX
HI NENC has played a key role in helping IBEX move towards real-world adoption, providing expert guidance, strategic support, and connections within the NHS.
As part of the National Women’s Health Accelerator, IBEX received mentoring and insights to shape its approach to NHS adoption. HI NENC also showcased IBEX at its Women’s Health event, helping to raise awareness and connect the company with healthcare leaders.
Through the NHS Opportunity and Technology Adoption (NOTCA) programme, HI NENC has supported IBEX in refining its value proposition, gathering evidence and navigating the complex NHS landscape. Now in the spread and adoption phase of HI NENC’s innovation gateway, IBEX is progressing through the Digital Technology Assessment Criteria (DTAC) process, ensuring it meets NHS standards.
Paul Scott – CEO at IBEX Innovations:
Developing a cutting-edge medical product is only half the battle. HINENC has been instrumental in helping us connect with healthcare professionals to fully establish the clinical value of our bone health product and refine it to best serve the NHS. This support has been crucial in securing our first NHS adopters, partnering with two leading X-ray OEMs, and successfully raising £2m to drive commercialisation. HI NENC’s guidance during this critical phase has been invaluable.
What’s next for IBEX?
Following a successful fundraising round, IBEX is now working with Agfa Radiology to drive adoption across the UK. Its first trial site at Royal Cornwall Hospital is gearing up to being trials of the software in clinical practice. A second study is due to start at Addenbrooke’s Hospital who will be assessing the workflow impact of providing a bone health assessment alongside a mammogram for women receiving breast cancer treatment. This study is funded from an Innovate UK Biomedical Catalyst grant specially set up for companies participating in the Femtech Accelerator programme.
IBEX is working with the NHS as a foundation for growth with ambitions to expand internationally. By making osteoporosis detection simpler, earlier and more accessible, this technology has the potential to reduce fractures, improve patient outcomes, and relieve pressure on the healthcare system.
Find out more about the brilliant work IBEX Innovations do here: Home – IBEX Innovations